FKnol.com

Financial Knowledge & Information Portal

Amgen (AMGN) Company Profile

Updated May 3, 2019
Amgen has the following business profile:
Company's Full Name:Amgen Inc
Short Name:Amgen
Trading Ticker Symbol:AMGN
Primary Exchange:NASDAQ
Headquarter City/Country:Thousand Oaks, California
Primary Industry Sector:Health Care
Seconday Sub-sector:Biotech Biological Products
Main Business Areas: Health Care, Biotech Biological Products, Biotech Products, Major Drug Manufacturers, NASDAQ
Dividend Payments:Dividend History

Market and Trading Information for Amgen

The following details were available for trading and market data about the stock of Amgen as of writing:
Current Share Price:$177.31
Previous Year's Closing Price:$194.66
Percentage Price Change (YTD):-8.91%
Market Cap:$108.15 billion
52-week Price Range:$167.09 - $210.19
Dividend Per Share:$5.41
EPS (TTM):12.62
Price-Earnings (Trailing):14.05
Price-Earnings (Forward):11.99

Company Profile and Business Description for Amgen

Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. The Company's marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The Company's product candidates in Phase III include Erenumab for episodic migraine; Aranesp for myelodysplastic syndromes; BLINCYTO for acute lymphoblastic leukemia (ALL); ENBREL for psoriatic arthritis and rheumatoid arthritis remission; IMLYGIC for metastatic melanoma; Kyprolis for multiple myeloma; Prolia for glucocorticoid-induced osteoporosis; Repatha for hyperlipidemia; XGEVA for delay or prevention of bone metastases in breast cancer and also for the treatment of cancer-related bone damage in patients with multiple myeloma; Vectibix for metastatic colorectal cancer (mCRC); Omecamtiv mecarbil for chronic heart failure, and EVENITY for postmenopausal osteoporosis and male osteoporosis. The Company's product candidates in Phase II include BLINCYTO for diffuse Large B-Cell Lymphoma (DLBCL) and relapsed/refractory Philadelphia positive (R/R Ph+) and minimal residual disease of ALL; Erenumab for Chronic migraine; AMG 157 for asthma and atopic dermatitis; AMG 520 for Alzheimer's disease, and AMG 899 for dyslipidemia.

The Company's product candidates in Phase I include IMLYGIC for various cancer types; KYPROLIS for small-cell lung cancer; Oprozomib for multiple myeloma; AMG 176 for various cancer types; AMG 211 for various cancer types; AMG 224 for multiple myeloma, and AMG 301 for migraine. The Company's product candidates in Phase I also include AMG 330 for acute myeloid leukemia; AMG 420 for multiple myeloma; AMG 557 for systemic lupus erythematosus; AMG 570 for systemic lupus erythematosus; AMG 592 for inflammatory diseases; AMG 820 for various cancer types, and AMG 986 for heart failure.

The Company markets ENBREL primarily in the United States. ENBREL is used primarily in the indications for the treatment of adult patients with various conditions, such as moderately to severely active rheumatoid arthritis, chronic moderate-to-severe plaque psoriasis patients, and active psoriatic arthritis. The Company markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the United States and Europe. Neulasta is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid) receiving anti-cancer medicines (chemotherapy) that can cause fever and a low blood cell count. It markets Aranesp primarily in Europe and in the United States. Aranesp is indicated for the treatment of anemia caused by chronic kidney disease (CKD) in both patients on dialysis and patients not on dialysis. Aranesp is also indicated for the treatment of anemia due to concomitant myelosuppressive chemotherapy in patients with non-myeloid malignancies. It markets EPOGEN in the United States for dialysis patients. EPOGEN is indicated to treat anemia caused by CKD in patients on dialysis to lessen the need for red blood cell transfusions.

The Company markets cinacalcet as Sensipar primarily in the United States and as Mimpara primarily in Europe. Cinacalcet is used primarily in the indication for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with CKD on dialysis. The Company markets XGEVA primarily in the United States and Europe. XGEVA is used primarily in the indication for the prevention of skeletal-related events (SREs), such as pathological fracture, radiation to bone, spinal cord compression or surgery to bone, in patients with bone metastases from solid tumors. It markets Prolia primarily in the United States and Europe. In the United States, Prolia is used primarily in the indication for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients having failed or are intolerant to other available osteoporosis therapy. In Europe, Prolia is used primarily for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. It markets NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), primarily in the United States, Canada and Europe. NEUPOGEN is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid) receiving anti-cancer medicines (chemotherapy) that can cause fever and a low blood cell count.

The Company competes with Johnson & Johnson, Merck & Company, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Galenica Group, F. Hoffmann-La Roche Ltd., Novartis, Takeda Pharmaceutical Company Limited, Celgene Corporation, Sanofi and Regeneron Pharmaceuticals, Inc.

1 Amgen Center Dr

Peer / Competitor Companies of Biotech Biological Products Sector

Along with Amgen Inc, the following other peer (competitor) companies also exist within the same Biotech Biological Products - Health Care sector whose company profile and dividend history is as follows:

▶ Acceleron Pharma (XLRN): Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare ....See Detailed Company Profile  and Dividend History.

▶ Acorda Therapeutics (ACOR): Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. ....See Detailed Company Profile  and Dividend History.

▶ Adaptimmune Therapeutics (ADAP): Adaptimmune Therapeutics plc, incorporated on December 03, 2014, is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) ....See Detailed Company Profile  and Dividend History.

▶ ADMA Biologics (ADMA): ADMA Biologics, Inc., incorporated on June 2, 2006, is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious ....See Detailed Company Profile  and Dividend History.

▶ Adverum Biotechnologies (ADVM): Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., incorporated on July 17, 2006, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from ....See Detailed Company Profile  and Dividend History.

▶ Aerie Pharma (AERI): Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients ....See Detailed Company Profile  and Dividend History.

▶ Aevi Genomic Medicine (GNMX): Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., incorporated on January 27, 2000, is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate ....See Detailed Company Profile  and Dividend History.

▶ Agenus (AGEN): Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display,....See Detailed Company Profile  and Dividend History.

▶ AmpliPhi Biosciences (APHB): AmpliPhi Biosciences Corporation, incorporated on March 9, 1989, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in ....See Detailed Company Profile  and Dividend History.

▶ Apollo Endosurgery (APEN): Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. It develops and distributes devices for minimally invasive surgica....See Detailed Company Profile  and Dividend History.

▶ Applied Genetic (AGTC): Applied Genetic Technologies Corporation, incorporated on October 24, 2003, is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases ....See Detailed Company Profile  and Dividend History.

▶ Aptose Biosciences (APTO): Aptose Biosciences Inc. (Aptose), incorporated on November 1, 2006, is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and ....See Detailed Company Profile  and Dividend History.

▶ ARIAD Pharma (ARIA): ....See Detailed Company Profile  and Dividend History.

▶ Asterias Biotherapeutics (AST): Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. ....See Detailed Company Profile  and Dividend History.

▶ Atara Biotherapeutics (ATRA): Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates ....See Detailed Company Profile  and Dividend History.

▶ aTyr Pharma (LIFE): aTyr Pharma, Inc., incorporated on October 8, 2005, is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, ....See Detailed Company Profile  and Dividend History.

▶ Audentes Therapeutics (BOLD): Audentes Therapeutics, Inc., incorporated on November 13, 2012, is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening ....See Detailed Company Profile  and Dividend History.

▶ AveXis (AVXS): AveXis, Inc., incorporated on March 10, 2010, is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic ....See Detailed Company Profile  and Dividend History.

▶ Aviragen Therapeutics (AVIR): Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., incorporated on March 14, 1969, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The ....See Detailed Company Profile  and Dividend History.

▶ Bavarian Nordic ADR (BVNRY): Bavarian Nordic A S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. T....See Detailed Company Profile  and Dividend History.

... See Full List of All Stocks of Biotech Biological Products Sector.

Stock List of Other Health Care Sub-sectors

▶ Stocks of Sector

▶ Stocks of Biotech Sector

▶ Stocks of Biotech Apparatus Sector

▶ Stocks of Biotech Diagnostics Sector

▶ Stocks of Biotech Products Sector

▶ Stocks of Biotech Research Sector

▶ Stocks of Drug Delivery Sector

▶ Stocks of Drug Development Sector

▶ Stocks of Drug Manufacturer Sector

▶ Stocks of Health Care Sector

▶ Stocks of Health Care Equipment and Services Sector

▶ Stocks of Hospital and Nursing Management Sector

▶ Stocks of Industrial Specialties Sector

▶ Stocks of Major Pharmaceuticals Sector

▶ Stocks of Medical Dental Instruments Sector

▶ Stocks of Medical Electronics Sector

▶ Stocks of Medical Nursing Services Sector

▶ Stocks of Medical Products Sector

▶ Stocks of Medical Specialities Sector

▶ Stocks of Ophthalmic Goods Sector

▶ Stocks of Other Pharmaceuticals Sector

▶ Stocks of Precision Instruments Sector


Stock List of Other Top-level Sectors

▶ Stocks of Sector

▶ Stocks of Basic Industries Sector

▶ Stocks of Basic Materials Sector

▶ Stocks of Capital Goods Sector

▶ Stocks of Communication Services Sector

▶ Stocks of Consumer Cyclical Sector

▶ Stocks of Consumer Defensive Sector

▶ Stocks of Consumer Durables Sector

▶ Stocks of Consumer Non-Durables Sector

▶ Stocks of Consumer Services Sector

▶ Stocks of Energy Sector

▶ Stocks of Finance Sector

▶ Stocks of Financial Services Sector

▶ Stocks of Health Care Sector

▶ Stocks of Industrials Sector

▶ Stocks of Miscellaneous Sector

▶ Stocks of Public Utilities Sector

▶ Stocks of Real Estate Sector

▶ Stocks of Services Sector

▶ Stocks of Technology Sector

▶ Stocks of Transportation Sector

▶ Stocks of Utilities Sector